11 completed, 1 active not recruiting, 1 withdrawn. 13 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 11, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Dermatitis, Contact: new trials by email Literature Review of Dermatitis, Contact trials Research Report on Dermatitis, Contact
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab - Skin Inflammation, Allergic Contact Dermatitis | Phase 2 / Phase 3 | Active not recruiting | Wei-Che Ko | 45 | 2022-11-15 | 2026-06-09 |
| Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0% - Allergic Contact Dermatitis | Phase 2 | Completed | Edesa Biotech Inc. | 211 | 2019-10-15 | 2024-11-14 |
| Mechlorethamine Induced Contact Dermatitis Avoidance Study Triamcinolone, Valchlor 0.016 % Topical Gel - Cutaneous T-cell Lymphoma, Cutaneous T-cell Lymphoma Stage I | Phase 2 | Completed | Rochester Skin Lymphoma Medical Group, PLLC | 28 | 2017-12-13 | 2026-09-04 |
| Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study Ammoniated mercury, Aluminum chloride and aluminum lactate, Sodium tetrachloropalladate - Contact Dermatitis | Phase 2 | Completed | Allerderm | 56 | 2013-11-04 | 2020-08-24 |
| Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light Solar Protection Formula SPF® 60, Photobiological testing - High-grade Dysplasia in Barrett Esophagus, Non Small Cell Lung Cancer | Phase 2 | Withdrawn | Pinnacle Biologics Inc. | 2013-05-01 | 2014-03-04 | |
| Clinical Evaluation of Lyral® Dose Response Study Lyral® - Contact Dermatitis | Phase 2 | Completed | Allerderm | 22 | 2013-02-01 | 2023-07-28 |
| Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis MRX-6, Steroid - Allergic Contact Dermatitis | Phase 1 / Phase 2 | Completed | Hadassah Medical Organization | 13 | 2011-03-01 | 2015-04-21 |
| Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis rHuPH20, Placebo - Dermatitis, Allergic Contact | Phase 2 | Completed | Halozyme Therapeutics | 22 | 2009-06-23 | 2021-12-17 |
| Study of Apremilast in Atopic or Contact Dermatitis Apremilast - Atopic Dermatitis, Allergic Contact Dermatitis | Phase 2 | Completed | Tufts Medical Center | 10 | 2009-06-01 | 2010-12-20 |
| Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens - Contact Dermatitis | Phase 2 | Completed | Allerderm | 48 | 2008-04-01 | 2018-04-09 |
| Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations TRUE Test allergens Fragrance Mix and Thimerosol - Dermatitis, Contact | Phase 2 | Completed | Allerderm | 50 | 2008-01-01 | 2018-04-09 |
| Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate Goldnatriomthiosulphate, MDBGN, parthenolide - Allergic Contact Dermatitis | Phase 2 | Completed | Mekos Laboratories AS | 60 | 2005-04-01 | 2006-02-27 |
| Clinical Evaluation of Bacitracin bacitracin (allergen) - Allergic Contact Dermatitis | Phase 2 | Completed | Mekos Laboratories AS | 20 | 2005-04-01 | 2005-10-19 |
Dermatitis, Allergic Contact (7) · Dermatitis (3) · Eczema (2) · Carcinoma, Non-Small-Cell Lung (1) · Dermatitis, Atopic (1) · Dermatitis, Phototoxic (1) · Esophageal Neoplasms (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1)
Skin Diseases (13) · Skin Diseases, Eczematous (13) · Skin and Connective Tissue Diseases (13) · Dermatitis (10) · Immune System Diseases (8) · Hypersensitivity (7) · Hypersensitivity, Delayed (7) · Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dermatitis, Irritant (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
Triamcinolone Acetonide (2) · 1,2-dibromo-2,4-dicyanobutane (1) · Adalimumab (1) · Allergens (1) · Amines (1) · Bacitracin (1) · Betamethasone Valerate (1) · Fluticasone (1) · Gels (1) · Mechlorethamine (1) · Ointments (1) · Steroids (1) · Thimerosal (1) · Triamcinolone (1) · Ustekinumab (1)
Allerderm (4) · Mekos Laboratories AS (2) · Edesa Biotech Inc. (1) · Hadassah Medical Organization (1) · Halozyme Therapeutics (1) · Pinnacle Biologics Inc. (1) · Rochester Skin Lymphoma Medical Group, PLLC (1) · Tufts Medical Center (1) · Wei-Che Ko (1)
United States (8) · Denmark (3) · Canada (1) · Israel (1) · Sweden (1)
Joseph Fowler, MD (2) · Alice B. Gottlieb, M.D., PhD. (1) · Brian Poligone, MD, PhD (1) · Donald V. Belsito, MD (1) · Evy Paulsen, M.D., Ph.D (1) · Evy Paulsen, Md, PhD (1) · Ikeadi M Ndukwu, M.D., MPH (1) · Jerri Hoskyn, MD (1) · Joseph Fowler, Prof. (1) · Klaus E Andersen, Prof. (1) · Luz Fonacier, MD (1) · Marlene Isaksson, MD (1) · Wei-Che Ko, MD (1) · Yuval Ramot, MD (1)